Physician
Suh, Hester
Suh, Hester was paid $2.88M by Medicaid between Jan 2018 and Jul 2024, across 81 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider infoSUH, HESTER
SHREVEPORT, LA 71118
SHREVEPORT, LA 71118
33aNPI1407042435assigned 09/24/2007
33bProvider typePediatrics Physician
28Total paid$2.88M
24GClaims105,575
24DCodes billed81
24AFirst – last monthJan 2018 – Jul 2024
Compared with peers
Next to other Pediatrics Physician providers in Louisiana
Rank by total paid#45 of 230
Median peer was paid$429K
This provider vs. median6.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,143 | $366K | |
| 2019 | 33,681 | $875K | |
| 2020 | 24,342 | $564K | |
| 2021 | 12,813 | $385K | |
| 2022 | 9,240 | $314K | |
| 2023 | 10,299 | $346K | |
| 2024incomplete | 1,057 | $33K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 13,681 | 11,271 | $886K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 9,520 | 8,179 | $416K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 8.0% | 4,051 | 3,387 | $230K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.7% | 2,832 | 2,389 | $165K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 4.4% | 9,996 | 8,821 | $128K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.0% | 4,413 | 3,801 | $115K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.0% | 525 | 231 | $86K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.0% | 1,410 | 1,266 | $85K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 2.8% | 5,366 | 4,735 | $82K |
| 87631 | 2.8% | 1,226 | 671 | $80K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 565 | 507 | $55K |
| 99188 | 1.8% | 2,824 | 2,305 | $53K |
69 more codes
| 99383 | 1.4% | 578 | $41K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.3% | 1,081 | $38K |
| 99381 | 1.3% | 548 | $37K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.2% | 512 | $36K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 1,417 | $32K |
| 92551 | 1.0% | 4,237 | $30K | |
| 99382 | <1% | 424 | $28K | |
| 0240U | <1% | 287 | $24K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 598 | $23K |
| 54450 | <1% | 396 | $21K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 844 | $19K |
| 69210 | <1% | 914 | $19K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 269 | $17K |
| 90474 | <1% | 2,002 | $16K | |
| 83655 | <1% | 1,995 | $16K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 187 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,004 | $12K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 791 | $9K |
| 99384 | <1% | 117 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 246 | $8K |
| 99173 | <1% | 4,469 | $7K | |
| 54150 | <1% | 56 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 65 | $5K |
| 94664 | <1% | 630 | $5K | |
| 85018 | <1% | 2,377 | $4K | |
| 0071A | <1% | 77 | $3K | |
| 0002A | <1% | 93 | $3K | |
| 0072A | <1% | 66 | $3K | |
| 99460 | <1% | 64 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 205 | $2K |
| 87807 | <1% | 148 | $2K | |
| 0001A | <1% | 56 | $2K | |
| 96160 | <1% | 449 | $2K | |
| 90620 | <1% | 140 | $2K | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 12 | $2K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 34 | $1K |
| 36416 | <1% | 1,757 | $944.12 | |
| 17250 | <1% | 17 | $833.12 | |
| 90686 | <1% | 4,161 | $449.28 | |
| A7016 | Dome and mouthpiece, used with small volume ultrasonic nebulizer | <1% | 201 | $359.45 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 18 | $359.31 |
| 81002 | <1% | 154 | $311.97 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 33 | $230.00 |
| 96161 | <1% | 30 | $203.50 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 227 | $157.29 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 80 | $90.08 |
| 94760 | <1% | 276 | $63.53 | |
| 97802 | <1% | 94 | $48.18 | |
| 90633 | <1% | 1,634 | $2.05 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 111 | $1.80 |
| 90651 | <1% | 719 | $0.78 | |
| 91300 | 0% | 144 | $0.00 | |
| 90734 | 0% | 280 | $0.00 | |
| 90700 | 0% | 366 | $0.00 | |
| 90710 | 0% | 1,043 | $0.00 | |
| 90648 | 0% | 2,914 | $0.00 | |
| 90670 | 0% | 2,772 | $0.00 | |
| 90681 | 0% | 18 | $0.00 | |
| 90715 | 0% | 131 | $0.00 | |
| 90707 | 0% | 25 | $0.00 | |
| 90671 | 0% | 44 | $0.00 | |
| 90680 | 0% | 1,993 | $0.00 | |
| 90698 | 0% | 73 | $0.00 | |
| 90723 | 0% | 1,978 | $0.00 | |
| 90696 | 0% | 171 | $0.00 | |
| 90744 | 0% | 52 | $0.00 | |
| 91307 | 0% | 162 | $0.00 | |
| 90619 | 0% | 75 | $0.00 | |
| 90716 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.